News

Patients with cancer undergoing stem cell transplant are experiencing depression at higher rates than other cancer survivors, and special interventions are required to address their psychosocial needs.

The Food and Drug Administration granted accelerated approval to zanubrutinib for the treatment of relapsed and refractory mantle cell lymphoma.

Lung cancer treatments are advancing. With these changes come new complications and questions that nurses will have to address with their patients.

Multiple CDK4/6 inhibitors have shown impressive OS survival benefit in multiples studies of patients with metastatic HR+ breast cancer.

The FDA has granted a priority review to the combination treatment of nivolumab and ipilimumab to treat patients with advanced HCC.

The therapy is now approved for the treatment of anemia in adult patients with beta thalassemia who require regular red blood cell (RBC) transfusions.

With the help of NGS, new research is emerging for targeted therapies of rare mutations in lung cancer.

Precision medicine is sweeping across the cancer care spectrum, and now, experts have their sights set on applying it in MCL.

Steps in orthopedic oncology are being made after the first-ever global perspective trial in its field completed patient accrual.

New study results show that chemoimmunotherapy combination options provide an overall survival benefit to patients with stage IV nonsquamous NSCLC.

The FDA has approved the biosimilar pegfilgrastim for treatment to decrease the incidence of infection exhibited from febrile neutropenia.

Wnt emerges as an exciting and favorable pathway for the treatment of patients with CRC.

President Trump has announced he will be nominating Stephen M. Hahn, MD, FASTRO, to be the next commissioner of the FDA.

Patients with cancer are faced with chronic pain that nurses often cannot manage properly due to outdated restrictions and practices.

Any patient with cancer needs a caregiver through the treatment journey, but it's even more vital for patients with cancer undergoing the stem cell transplant process.

The FDA has granted an RMAT designation for an investigational CAR-T cell therapy used to treat patients with multiple myeloma.

Here are the top 5 Oncology Nursing News® stories for October 2019.

Frahad Ravandi-Kashani, MD, had the chance to discuss the role of MRD in treating patients with hairy cell leukemia.

New therapeutic options are emerging for patients with Lung cancer positive for ALK or ROS1.

The NDA for Blueprint Medicines' agent avapritinib will be split into two separate submissions for patients with GIST.

An update to the biologics license application of eflapegrastim has been resubmitted to the FDA to include chemo-induced neutropenia.

Following concerns over breast implant-associated cancer and illnesses, the Food and Drug Administration issued draft guidelines for additional labeling measures on devices.

Results from the phase III CARD trial suggest positive outcomes for patients with advanced prostate cancer on a novel treatment chemotherapy combination therapy treatment.

At the 2019 ESMO Congress, the phase II KATE2 trial missed its primary endpoint but found promising results for a subgroup of patients with HER2-positive breast cancer with a PD-L1 expression.

The FDA approves the use of niraparib in the treatment of patients with HRD-positive advanced ovarian cancer based on results from the phase II QUADRA study.

The FDA has expanded the approval of aprepitant to include in its label the use of a single dose regimen in patients receiving moderately epigenetic chemotherapy.

Immunotherapy is sometimes considered solely for the later stages of treatment, but findings from a new study show promise for immunotherapy in treating patients with early breast cancer.

ACCC is celebrating the 15th anniversary of Oncology Pharmacy Education Network by honoring its founders.